Jump to content

  • Log in with Facebook Log in with Twitter Log in with Windows Live Log In with Google      Sign In   
  • Create Account

Submit your paper to J Biol Methods today!
Photo
- - - - -

Recombinant protein or peptide?


  • Please log in to reply
1 reply to this topic

#1 craigGFFKR

craigGFFKR

    member

  • Members
  • Pip
  • 4 posts
0
Neutral

Posted 05 May 2009 - 12:53 PM

I am researching the role of the 18-amino acid cytoplasmic domain of a transmembrane receptor. I want to do a couple things: 1) screen cell lysates to see which proteins associate with this cytoplasmic domain, 2) transduce the cytoplasmic domain into cells via a cell-penetrating TAT sequence to determine if it is inhibitory (by sequestering binding proteins from the endogenous receptor).

I have several questions:
1) Can such a short sequence be successfully expressed as a recombinant protein with, for example, a GST tag? This would be ideal to accomplish #1 above as lysates can simply be run over the affinity column on which the protein was purified.
2) I was working under the assumption that I would need to order custom peptides to accomplish #2 above, but would it be possible to simply express the TAT and target sequence as a single protein, purify with affinity tag, then cleave the tag?

Thanks in advance for any help!

#2 LifeTein Peptide

LifeTein Peptide

    Protein and Peptide Expert

  • Active Members
  • Pip
  • 17 posts
0
Neutral

Posted 07 May 2009 - 08:41 AM

1. no problem to add the GST with your 18 aa. I have done this successfully.
2. I am the peptide guy from Lifetein, a peptide company. If you know the peptide region is the binding site, you should try the synthesized peptides. I do not want to do ads here form my company but your idea of using peptide is sound. Email me if you have any questions: jamesc@lifetein.com
LifeTein, The Peptide Company
www.lifetein.com
@lifetein

Understanding Life One Protein At a Time...





Home - About - Terms of Service - Privacy - Contact Us

©1999-2013 Protocol Online, All rights reserved.